The firm's lead product is Hyleukin-7TM, an engineered T-cell amplifier designed to reconstitute and enhance antitumoral T-cell immunity.

In December 2019, it was announced that this candidate will enter a trial alongside Merck & Co's blockbuster anti-PD1 therapy, Keytruda (pembrolizumab), in relapsed/refractory advanced solid tumors.